Neurogene (NGNE) Return on Capital Employed (2014 - 2026)
Neurogene (NGNE) posted Return on Capital Employed of 43.1% for Q1 2026, down 13.36% on a QoQ basis from 38.01% in Q4 2025, and down 1428.0% year-over-year from 3.25% in Q1 2025.
Neurogene (NGNE) Return on Capital Employed (2014 - 2026) Analysis & Trends
Neurogene's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 43.1% for Q1 2026.
- Quarterly Return on Capital Employed fell 1428.0% year-over-year to 43.1% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.1% (down 1428.0% YoY) and the FY2025 annual result came in at 34.94%, down 365.0% from the prior year.
- Return on Capital Employed was 43.1% for Q1 2026 at Neurogene, down from 38.01% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.82% in Q1 2025 and bottomed at 60.66% in Q3 2023.
- A 5-year average of 43.17% and a median of 41.76% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 2206 bps — and 2024, when it soared 2492 bps.
- Neurogene's Return on Capital Employed stood at 50.79% in 2022, then advanced by 18 bps to 41.76% in 2023, then grew by 16 bps to 35.19% in 2024, then slipped by 8 bps to 38.01% in 2025, then decreased by 13 bps to 43.1% in 2026.
- Business Quant data shows NGNE's Return on Capital Employed at 43.1% in Q1 2026, 38.01% in Q4 2025, and 35.02% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Neurogene | 17.50 Mn | 17.50 Mn | - | -43.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -43.10% |
| Dec 31, 2025 | -38.01% |
| Sep 30, 2025 | -35.02% |
| Jun 30, 2025 | -32.90% |
| Mar 31, 2025 | -28.82% |
| Dec 31, 2024 | -35.19% |
| Sep 30, 2024 | -48.55% |
| Jun 30, 2024 | -39.46% |
| Mar 31, 2024 | -31.11% |
| Dec 31, 2023 | -41.76% |
| Sep 30, 2023 | -60.66% |
| Jun 30, 2023 | -55.73% |
| Mar 31, 2023 | -56.03% |
| Dec 31, 2022 | -50.79% |
| Sep 30, 2022 | -49.37% |
| Jun 30, 2022 | -46.23% |
| Mar 31, 2022 | -41.13% |
| Dec 31, 2021 | -37.71% |
| Sep 30, 2021 | -33.72% |
| Jun 30, 2021 | -24.17% |